Coordinated Antimicrobial Drug/Device Development Addressed In FDA Final Guidance
Executive Summary
In its bid to fight antimicrobial resistance, the agency has finalized a 2016 guidance on how novel antibiotic developers can coordinate with antimicrobial susceptibility test-makers to ensure their products come to market at about the same time. The agency recommends using its pre-submission process for a more efficient review.
You may also be interested in...
Coordinating Antibiotics, Test Development Could Shorten Approval Times, US FDA Says
In a new draft guidance, the agency recommends antimicrobial drug developers and sponsors of antimicrobial susceptibility tests coordinate their regulatory submissions to get their products on the market together faster.
Massive Family Dollar Rat Infestation Leads To Multi-State Recall
The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.
Digital Health Roundup: Exec Chats With Illumina, Bloom, AngelMed; M&A, Funding; FDA Down-Classifies Apps
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights IBM Watson Health’s divestiture and other financing news, Exec Chats with Illumina, AngelMed and Bloom, Philips’ new hand-held ultrasound device and autonomous robotic surgery, as well as the latest FDA news on digital health.